NexGard Chewables

NexGard for Dogs - 3 month
4-10 lbs (3pk) - (orange
4-10 lbs (6pk) - (orange)
4-10 lbs (12pk) - (orange)
10.1-24 lbs (3pk) - (blue)
10.1-24 lbs (6pk) - (blue)
10.1-24 lbs (12pk) - (blue)
24.1-60 lbs (3pk) - (purple)
24.1-60 lbs (6pk) - (purple)
24.1-60 lbs (12pk) - (purple)
60.1-121 lbs (3pk) - (red)
60.1-121 lbs (6pk) - (red)
60.1-121 lbs (12pk) - (red)
SKU : 5531_-RX
Price: $55.95
Veterinarian Prescription (Rx) Required
Free Shipping on orders over $75
Low Price Match Guarantee
  • The first and only chew that kills BOTH fleas AND ticks
  • NOW available in a 6-dose pack!
  • Protection so tasty, they’ll beg for it
  • Brought to you by the maker of FRONTLINE®
  • Now kills EVEN MORE ticks:
    • American dog ticks
    • Lone star ticks
    • Black-legged (deer) ticks that may spread Lyme disease
RX required for this item.
Click here for our full Prescription Policy and Form

  • Its irresistible beef flavor makes it easy to give
  • It kills fleas fast, before they lay eggs, preventing infestation
  • And, it kills American dog Ticks, Lone star ticks, Black-legged (deer) ticks

NexGard, which has demonstrated excellent efficacy at low dose, is the first and only soft beef-flavored chew approved to kill both fleas and ticks. It contains the novel active ingredient afoxolaner, an isoxazoline based compound with a new and distinct mode of action.

Customer Reviews
# of Ratings: 3
CAUTION: Federal (USA) law restricts this drug to use by or on the order of
a licensed veterinarian.

NEXGARD™ (afoxolaner) is available in four sizes of beef-flavored, soft chewables
for oral administration to dogs and puppies according to their weight. Each chewable
is formulated to provide a minimum afoxolaner dosage of 1.14 mg/lb (2.5 mg/kg).
Afoxolaner has the chemical composition 1-Naphthalenecarboxamide, 4-[5- [3-chloro-5-
(trifluoromethyl)-phenyl]-4, 5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2-

NEXGARD kills adult fleas and is indicated for the treatment and prevention of fl ea
infestations (Ctenocephalides felis), and the treatment and control of American Dog
tick (Dermacentor variabilis) infestations in dogs and puppies 8 weeks of age and older,
weighing 4 pounds of body weight or greater, for one month.

Dosage and Administration:
NEXGARD is given orally once a month, at the minimum dosage of 1.14 mg/lb (2.5 mg/kg).

Dosing Schedule:
Body  Afoxolaner Per Chewables
Weight  Chewable (mg)  Administered
4.0 to 10.0 lbs.  11.3 One
10.1 to 24.0 lbs.  28.3 One
24.1 to 60.0 lbs. 68 One
60.1 to 121.0 lbs. 136 One
Over 121.0 lbs.  Administer the appropriate combination of chewables

NEXGARD can be administered with or without food. Care should be taken that the dog
consumes the complete dose, and treated animals should be observed for a few minutes to
ensure that part of the dose is not lost or refused. If it is suspected that any of the dose has
been lost or if vomiting occurs within two hours of administration, redose with another full
dose. If a dose is missed, administer NEXGARD and resume a monthly dosing schedule.

Flea Treatment and Prevention:
Treatment with NEXGARD may begin at any time of the year. In areas where fleas are
common year-round, monthly treatment with NEXGARD should continue the entire year
without interruption.

To minimize the likelihood of fl ea reinfestation, it is important to treat all animals within a
household with an approved fl ea control product.

Tick Treatment and Control:
Treatment with NEXGARD may begin at any time of the year (see Effectiveness).

There are no known contraindications for the use of NEXGARD.

Not for use in humans. Keep this and all drugs out of the reach of children. In case of
accidental ingestion, contact a physician immediately.

The safe use of NEXGARD in breeding, pregnant or lactating dogs has not been evaluated.
Use with caution in dogs with a history of seizures (see Adverse Reactions).

Adverse Reactions:
In a well-controlled US field study, which included a total of 333 households and 615
treated dogs (415 administered afoxolaner; 200 administered active control), no serious
adverse reactions were observed with NEXGARD.

Over the 90-day study period, all observations of potential adverse reactions were
recorded. The most frequent reactions reported at an incidence of > 1% within any of the
three months of observations are presented in the following table. The most frequently
reported adverse reaction was vomiting. The occurrence of vomiting was generally selflimiting
and of short duration and tended to decrease with subsequent doses in both
groups. Five treated dogs experienced anorexia during the study, and two of those dogs
experienced anorexia with the first dose but not subsequent doses.